Hepatis C virus genotype 4.

Hepatitis C virus genotype 4 chronic hepatitis predominates in the Eastern Mediterranean region of the world. In the Kingdom of Saudi Arabia, as high as 62% of all cases are due to genotype 4. Results of efficacy and safety clinical trials using pegylated-interferon plus ribavirin for chronic hepatitis C patients have shown great promise, but treatment of early responders should be maintained at 180 mg of pegylated-interferon alfa-2a plus 1000-1200 mg of ribavirin for 48 weeks unlike the 24 weeks recommended for genotypes 2 and 3. Hepatitis C genotype 4 may not be as "difficult to treat" as initially thought.

Keywords

Male, Clinical Trials as Topic, Dose-Response Relationship, Drug, Genotype, Saudi Arabia, Interferon-alpha, Genome, Viral, Hepacivirus, Hepatitis C, Chronic, Interferon alpha-2, Prognosis, Drug Administration Schedule, Recombinant Proteins, Treatment Outcome, Ribavirin, Humans, Drug Therapy, Combination, Female

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average